Information Provided By:
Fly News Breaks for June 13, 2016
AGIO
Jun 13, 2016 | 06:06 EDT
Canaccord Genuity analyst John Newman upgraded Agios Pharmaceuticals to Buy and raised his price target for the shares to $90 from $50 after the company's AG-348 achieved proof-of-concept in an ongoing Phase 2 study of patients with pyruvate kinase deficiency. JPMorgan this morning also upgraded Agios.
News For AGIO From the Last 2 Days
There are no results for your query AGIO